Success Metrics

Clinical Success Rate
93.8%

Based on 30 completed trials

Completion Rate
94%(30/32)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(6%)

Phase Distribution

Ph phase_4
2
6%
Ph phase_2
15
44%
Ph phase_1
6
18%
Ph phase_3
2
6%

Phase Distribution

6

Early Stage

15

Mid Stage

4

Late Stage

Phase Distribution25 total trials
Phase 1Safety & dosage
6(24.0%)
Phase 2Efficacy & side effects
15(60.0%)
Phase 3Large-scale testing
2(8.0%)
Phase 4Post-market surveillance
2(8.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.2%

30 of 34 finished

Non-Completion Rate

11.8%

4 ended early

Currently Active

0

trials recruiting

Total Trials

34

all time

Status Distribution
Completed(30)
Terminated(4)

Detailed Status

Completed30
Withdrawn2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
34
Active
0
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (24.0%)
Phase 215 (60.0%)
Phase 32 (8.0%)
Phase 42 (8.0%)

Trials by Status

withdrawn26%
completed3088%
terminated26%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT01561391Phase 4

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

Completed
NCT00124293

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Completed
NCT01564563Phase 2

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Terminated
NCT01561417Phase 1

Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Completed
NCT00426803Phase 2

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Completed
NCT01562821Phase 2

Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy

Completed
NCT00154492Phase 2

Use of NovoSeven® in Active Variceal Bleeding

Completed
NCT01563458Phase 2

Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation

Completed
NCT01601457Phase 2

Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction

Completed
NCT01563445Phase 2

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

Completed
NCT01563471Phase 1

Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers

Completed
NCT01563523Phase 2

Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients

Completed
NCT01562574Phase 3

Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease

Completed
NCT00104455Phase 1

Dose Response to Recombinant Factor VIIa When Administered for Bleed

Completed
NCT01562587Phase 1

Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State

Completed
NCT00123591Phase 2

Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury

Completed
NCT00571584Phase 4

High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Completed
NCT00108758Phase 2

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

Completed
NCT01779921

Treatment of Congenital Factor VII Deficiency

Completed
NCT00154427Phase 2

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
34